Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma

NCT00020462 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: autologous tumor cell vaccine

Sponsor

National Cancer Institute (NCI)